VacZine Analytics  
MarketVIEW: Campylobacter vaccines

Published: November 2016

Campylobacter jejuni is a major cause of gastroenteritis worldwide and is also associated with Guillain-Barré syndrome (GBS) and other complications. The main symptom, gastroenteritis occurs within 24–72 hours of ingestion. Infection usually manifests as acute watery or bloody diarrhoea, fever, weight loss and cramps that lasts ~6 days. Campylobacteriosis is the sixth most common known cause of diarrhoeal death in children aged <5 years. It is the also most common cause of bacterial gastroenteritis, responsible for 7.5 million DALYs in 2010. Campylobacter can also affect Western travellers to endemic countries

This MarketVIEW product is composed of is composed of a comprehensive MS Excel-based model + Summary Presentation that forecasts the potential commercial value of Campylobacter jejuni vaccines across 47 endemic countries to 2035. Three scenarios (LO, BASE and HI) are included based upon successive targeting of endemic countries based upon DALYs per WHO region. A travelers forecast from major Western points of origin is also included. The report covers a detailed review of disease background and epidemiology along with current treatment, unmet needs and rationale for vaccine approach. An ideal Target Product Profile (TPP) is defined along with commercial model assumptions with pricing justification.

THIS PRODUCT IS A SUMMARY PRESENTATION + 1 MODELs

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV071 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2016 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains